Madrigal Pharmaceuticals Reports Q3 Product Revenue of $431.268 Million
Story updates
12:06:56 PM UTC
SquawkNews
*-- Earnings Flash (MDGL) Madrigal Pharmaceuticals, Inc. Reports Q3 Revenue $431.3M, vs.
Related stories
Dynacor Enters US$20 Million Gold Purchase and Prepayment Facility
Dynacor Group entered into an unsecured US$20 million gold purchase and prepayment facility with Auramet International.
M impact | EQUITY | Nov 03, 2026, 01:16 PM UTC
SK hynix Reports 9.1% Stake in Penguin Solutions, Gains Board Nomination Rights
SK hynix reported a 9.1% beneficial stake through preferred shares convertible into 6,096,103 common shares. SHIFTIX1 LLC bought the preferred shares on October 29, 2026, for $377.
M impact | EQUITY | Nov 03, 2026, 01:16 PM UTC
SBI Estimates Rs 19,500 Crore Post-Tax Impact From ECL Framework
State Bank of India has put its expected credit loss models in place, Chairman C S Setty said. The bank will absorb the estimated impact through a phased transition.
M impact | EQUITY | Nov 03, 2026, 01:16 PM UTC
CACI Wins Five-Year, $108 Million U.S. Air Force Contract
CACI said it was awarded a five-year, $108 million contract by the U.S. Air Force to advance financial transparency, operational efficiency and mission readiness.
M impact | EQUITY | Nov 03, 2026, 01:16 PM UTC
Rankin Acquires 41,350 Shares Outside the Marketplace
Rankin acquired 41,350 shares at SEK 235.15 on Nov. 3, 2026, outside the marketplace.
M impact | EQUITY | Nov 03, 2026, 01:16 PM UTC
Petrobras shares fall more than 3% in early trading
M impact | EQUITY | Nov 03, 2026, 01:15 PM UTC